Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Meta-hydroxylamine plus dopamine versus norepinephrine for hemodynamics in shock
ChiCTR1900023896Phase 4Not yet recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of metahydroxylamine, dopamine and norepinephrine in Shock and Vasoplegia (2 arms), sponsored by Peking Union Medical College Hospital. Primary endpoint: 28-day survival rate. Planned start May 2019; status: not yet recruiting.
02
Drugs
metahydroxylaminedopaminenorepinephrine
03
Conditions
ShockVasoplegia
Beyond the preview
Go deeper on ChiCTR1900023896.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900023896.